|
Apr 25
|
Swiss Agree to Tariff Negotiations With Trump Administration
|
|
Apr 24
|
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
|
|
Apr 24
|
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
|
|
Apr 24
|
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
|
|
Apr 24
|
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
|
|
Apr 24
|
Sanofi stays on course amid tariff turmoil
|
|
Apr 24
|
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
|
|
Apr 24
|
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
|
|
Apr 23
|
Why vaccine makers aren't worried about Trump administration cuts
|
|
Apr 23
|
Update: Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|
|
Apr 23
|
European Equities Surge Higher in Wednesday Trading; EC Fines Meta, Apple for DMA Violations
|
|
Apr 23
|
Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|
|
Apr 23
|
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
|
|
Apr 23
|
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement
|
|
Apr 23
|
European pharma companies push for higher drug prices in EU amid U.S. tariff threats
|
|
Apr 22
|
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
|
|
Apr 21
|
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
|
|
Apr 21
|
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|
|
Apr 8
|
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
|